<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146442">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02091986</url>
  </required_header>
  <id_info>
    <org_study_id>D589GC00003</org_study_id>
    <nct_id>NCT02091986</nct_id>
  </id_info>
  <brief_title>A 12-Week Study in Asthmatic Children Ages 6 to &lt;12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg</brief_title>
  <acronym>CHASE 3</acronym>
  <official_title>A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 μg, 2 Actuations Twice Daily, Compared With Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to &lt;12 Years With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and
      Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in
      Children Ages 6 to &lt;12 Years with Asthma during 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study
      Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg, 2 Actuations Twice
      Daily, and Symbicort pMDI 80/4.5 μg, 2 Actuations Twice Daily, Compared with Budesonide pMDI
      80 μg, 2 Actuations Twice Daily, in Children Ages 6 to &lt;12 Years with Asthma
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in one-hour post-dose forced expiratory volume in the first second (FEV1)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 12 in one-hour post-dose FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in one-hour post-dose clinic FVC (L)</measure>
    <time_frame>Baseline taken at Week 0 then at Weeks 2, 4, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to one-hour post-dose FVC at Weeks 2, 4, 8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in one-hour post-dose clinic FEF25-75 (L/s) measured in the clinic</measure>
    <time_frame>Baseline taken at Week 0 then at Weeks 2,4,8 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to one-hour post-dose FEF25-75 at Weeks 2, 4, 8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in one-hour post-dose peak expiratory flow (PEF) (L/min) measured in the clinic (clinic PEF)</measure>
    <time_frame>Baseline taken at Week 0 then at Weeks 2,4,8 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to one-hour post-dose PEF at Weeks 2, 4, 8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in one-hour post-dose FEV1</measure>
    <time_frame>Weeks 2, 4 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in one-hour post dose FEV1 at Weeks 2, 4 and 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose clinic FEV1 in liter (L).</measure>
    <time_frame>Baseline to Week 2,4,8 and12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to pre-dose FEV1 at Weeks 2,4,8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose clinic FVC (L)</measure>
    <time_frame>Baseline to Week 2,4,8 and12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to pre-dose FVC (L) at Weeks 2,4,8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose clinic FEF25-75 (L/s)</measure>
    <time_frame>Baseline to Week 2,4,8 and12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to pre-dose FEF25-75 at Weeks 2,4,8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose clinic Peak expiratory flow (PEF) (L/min)</measure>
    <time_frame>Baseline to Week 2, 4, 8 and12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to pre-dose PEF at Weeks 2, 4, 8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fifteen-minute post-dose clinic FEV1 (L)</measure>
    <time_frame>Baseline taken at Week 0 then at Week 12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to one-hour post-dose FEV1 at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fifteen-minute post-dose clinic clinic FVC (L)</measure>
    <time_frame>Baseline taken at Week 0 then at Week 12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to one-hour post-dose FVC at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fifteen-minute post-dose clinic FEF25-75 (L/s)</measure>
    <time_frame>Baseline taken at Week 0 then at Week 12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to one-hour post-dose FEF25-75 at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fifteen-minute post-dose clinic PEF (L/min)</measure>
    <time_frame>Baseline taken at Week 0 then at Week 12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to one-hour post-dose clinic PEF (L/min) at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of first asthma exacerbation</measure>
    <time_frame>Randomized 12-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time in days from randomization until first exacerbation during the 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in nighttime awakenings due to asthma symptoms requiring reliever use recorded in the eDiary during the single blind run in and the double blind treatment periods</measure>
    <time_frame>Baseline taken as percentage of nighttime awakenings during the last 7 days of run-in. Week 12 taken as percentage of nighttime awakenings during Treatment Week 12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in percentage of nighttime awakenings from baseline Treatment Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in paediatric Asthma Quality of Life Questionnaire with Standardised Activities (PAQLQ[S]) scores (overall and each domain)</measure>
    <time_frame>Baseline taken at Week 0 then at Weeks 4, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline PAQLQ(S) to mean of Weeks 4, 8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in morning and evening FEV1 (L) recorded in the electronic diary (eDiary)</measure>
    <time_frame>Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline mean in diary FEV1 to mean at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in nighttime reliever medication use recorded in the eDiary</measure>
    <time_frame>Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from mean baseline to Treatment Week 12 mean in nighttime reliever medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daytime reliever medication use recorded in the eDiary</measure>
    <time_frame>Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from mean baseline to Treatment Week 12 mean in daytime reliever medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total daily reliever medication use recorded in the eDiary</measure>
    <time_frame>Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from mean baseline to Treatment Week 12 mean in total reliever medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in nighttime asthma symptom scores recorded in the eDiary</measure>
    <time_frame>Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from mean baseline score to mean score during Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daytime asthma symptom scores recorded in the eDiary</measure>
    <time_frame>Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from mean baseline score to mean score during Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total daily asthma symptom scores recorded in the eDiary</measure>
    <time_frame>Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from mean baseline score to mean score during Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation of investigational product (IP).</measure>
    <time_frame>Randomized 12-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time in days from randomization until discontinuation of investigational product during the 12-week treatment period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1116</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Symbicort pMDI 80/2.25 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort pMDI 80/4.5µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide pMDI 80µg, 2 acuations twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort pMDI</intervention_name>
    <description>Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily</description>
    <arm_group_label>Symbicort pMDI 80/2.25 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort pMDI</intervention_name>
    <description>Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily</description>
    <arm_group_label>Symbicort pMDI 80/4.5µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Budesonide pMDI</intervention_name>
    <description>Budesonide pMDI 80µg, 2 acuations twice daily</description>
    <arm_group_label>Budesonide pMDI</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a documented clinical diagnosis of asthma defined by the ATS for at least 6
             months prior to Visit 2

          -  Have a morning pre-bronchodilator clinic FEV1 measured at least 6 hours after the
             last dose of inhaled SABA and at least 48 hours after last dose of inhaled LABA of
             60% to 100% of predicted normal

          -  Demonstrated reversibility of clinic FEV1 of ≥12% from pre -albuterol/salbutamol
             level within 15 to 30 minutes after administration of a standard dose of
             albuterol/salbutamol.

        Exclusion Criteria:

          -  Have been hospitalized at least once or required emergency treatment more than once
             for an asthma-related condition during the 6 months prior to Visit 1

          -  Have required treatment with systemic corticosteroids (eg, oral, parenteral, or
             rectal) for any reason within the 6 weeks prior to Visit 1
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Pearlman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado Allergy Asthma Centers, PC, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carin Jorup, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Mölndal, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carola Halderman</last_name>
    <phone>+1 913-708-6155</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rolling Hills Estate</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Walton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>David Chiriqui</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma, children, budesonide pMDI</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Symbicort</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
